|
WO2020131656A1
|
|
Pathogen-associated molecular pattern molecules and rna immunogenic compositions and methods of using the compositions for treating cancer
|
|
WO2018148180A2
|
|
Materials and methods for identifying and treating cancer patients
|
|
MX2018010061A
|
|
Multigenome retroviral vector preparations and methods and systems for producing and using same.
|
|
AU2016354102A1
|
|
A retroviral vector for the administration and expression of replicon RNA expressing heterologous nucleic acids
|
|
MX2018005467A
|
|
Compositions comprising lentiviral vectors expressing il-12 and methods of use thereof.
|
|
CA2997749A1
|
|
Ny-eso-1 specific tcrs and methods of use thereof
|
|
KR20170032373A
|
|
Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
|
|
AU2015218365A1
|
|
Immunotherapy of cancer through combination of local and systemic immune stimulation
|
|
KR20160105813A
|
|
Compositions for use in the treatment of allergic conditions
|
|
WO2015035010A1
|
|
Vaccine compositions for drug addiction
|
|
CA2909221A1
|
|
Gla monotherapy for use in cancer treatment
|
|
RS57420B1
|
|
Vaccines for hsv-2
|
|
WO2013149167A1
|
|
Lentiviral vector particles having improved transduction efficiency for cells expressing dc- sign
|
|
US2015050307A1
|
|
Materials and methods for producing improved lentiviral vector particles
|
|
WO2012149307A2
|
|
Synthetic long peptide (slp)-based vaccines
|
|
WO2012141984A1
|
|
Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
|
|
AU2012217723A1
|
|
Methods for enhancing immunogen specific immune responses by vectored vaccines
|
|
EP2544718A1
|
|
Vaccines for pandemic influenza
|
|
EP2456786A1
|
|
Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein
|
